62. 発作性夜間ヘモグロビン尿症 Disease details / Clinical trials / Drug dev / DR info

ABP 959
   AMGEN INC.
      2017   Phase 3   EUCTR2017-001418-27-IT   Czech Republic;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States
   Amgen
      2019   Phase 3   NCT03818607   Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
ABP 959 - biosimilar TO eculizumab
   Amgen Inc.
      2020   Phase 3   EUCTR2017-001418-27-PT   Czech Republic;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2017-001418-27-IE   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2017-001418-27-FI   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-001418-27-SI   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-001418-27-NO   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-001418-27-NL   Germany;Italy;Korea, Republic of;Netherlands;Norway;Spain;United Kingdom
      2019   Phase 3   EUCTR2017-001418-27-DE   Czech Republic;France;Germany;Ireland;Italy;Netherlands;Norway;Slovenia;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2017-001418-27-CZ   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-001418-27-GB   Germany;Italy;Netherlands;Norway;Spain;United Kingdom
      2017   Phase 3   EUCTR2017-001418-27-ES   Czech Republic;Finland;France;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Norway;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom
ABP 959 - proposed biosimilar TO eculizumab
   Amgen Inc.
      2020   Phase 3   EUCTR2017-001418-27-SE   Brazil;Czech Republic;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
ACH-0144471
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-000665-79-IT   Italy;Korea, Republic of;New Zealand;United Kingdom
      2018   Phase 2   EUCTR2016-003526-16-IT   Italy;Korea, Republic of;New Zealand;United Kingdom;United States
      2018   Phase 2   EUCTR2016-002652-25-IT   Italy;Korea, Republic of;New Zealand;United Kingdom
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 3   EUCTR2019-003829-18-IT   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States
   Achillion Pharmaceuticals, Inc.
      2018   Phase 2   EUCTR2017-000665-79-GB   Italy;Korea, Republic of;New Zealand;United Kingdom
      2018   Phase 2   EUCTR2016-002652-25-GB   Italy;Korea, Republic of;New Zealand;United Kingdom
   Alexion Pharmaceuticals
      2017   Phase 2   NCT03181633   Italy;Korea, Republic of;New Zealand
      2017   Phase 2   NCT03053102   Italy;Korea, Republic of;New Zealand;United Kingdom
   Alexion Pharmaceuticals Inc.
      2021   Phase 3   EUCTR2019-003829-18-PL   Argentina;Brazil;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003829-18-NL   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003829-18-GB   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003829-18-FR   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2018   Phase 2   EUCTR2016-003526-16-GB   Italy;United Kingdom;United States
ACH-0145228
   Achillion Pharmaceuticals, Inc., a wholly owned subsidiary of Alexion Pharmaceuticals Inc.
      2021   Phase 2   EUCTR2019-003830-17-IT   Italy;Korea, Republic of;New Zealand;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003830-17-GB   Italy;Korea, Republic of;New Zealand;United Kingdom;United States
   Alexion Pharmaceuticals Inc.
      2021   Phase 2   EUCTR2019-003830-17-ES   Canada;France;Germany;Italy;Korea, Republic of;New Zealand;Spain;Turkey;United Kingdom
ACT-HIB
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-000665-79-IT   Italy;Korea, Republic of;New Zealand;United Kingdom
      2018   Phase 2   EUCTR2016-003526-16-IT   Italy;Korea, Republic of;New Zealand;United Kingdom;United States
ACT-HIB polvere E solvente PER soluzione iniettabile IN siringa preriempita 0,5 ML
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-003172-41-IT   China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
Acthib - polvere E solvente PER soluzione iniettabile 1 flaconcino polvere+1 siringa preriempita solvente 0.5 ML
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004385-19-IT   Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States
ADX-038
   ADARx Pharmaceuticals, Inc.
      2023   Phase 1/Phase 2   NCT05876312   Australia;United Kingdom
Allogeneic bone marrow transplantation
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Allogeneic hematopoietic stem cell transplantation
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States
      2009   -   NCT00856388   United States
Allogeneic stem cell transplantation
   St. Jude Children's Research Hospital
      2005   Phase 2   NCT00143559   United States
ALN-62643
   Alnylam Pharmaceuticals Inc
      2016   Phase 2   EUCTR2016-002943-40-ES   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Netherlands;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom
ALN-CC5
   Alnylam Pharmaceuticals
      2015   Phase 1/Phase 2   NCT02352493   Spain;United Kingdom
   Alnylam Pharmaceuticals Inc
      2016   Phase 2   EUCTR2016-002943-40-ES   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Netherlands;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom
   Aurand Lisa
      2024   Phase 3   JPRN-jRCT2031230013   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;South Korea;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2023   Phase 3   JPRN-jRCT2031220440   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;South Korea;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   REGENERON PHARMACEUTICALS, INC.
      2022   Phase 3   EUCTR2021-004931-10-IT   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-IT   Brazil;Canada;China;Colombia;France;Greece;Hungary;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Singapore;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
   Regeneron Pharmaceuticals, Inc.
      2023   Phase 3   EUCTR2021-004931-10-RO   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004931-10-PL   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004931-10-HU   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004931-10-GR   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-RO   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-PL   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-HU   Brazil;Canada;China;Colombia;France;Greece;Hungary;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-GR   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-ES   Brazil;Canada;China;Colombia;France;Greece;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Singapore;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-PL   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-GR   Brazil;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-FR   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-ES   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-DE   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-005005-17-HU   Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom
ALXN1102
   Alexion Pharmaceuticals
      2011   Phase 1   NCT01335165   Czech Republic;Italy;Poland;United Kingdom;United States
ALXN1103
   Alexion Pharmaceuticals
      2011   Phase 1   NCT01335165   Czech Republic;Italy;Poland;United Kingdom;United States
ALXN1210
   ALEXION PHARMACEUTICALS INCORPORATED
      2019   Phase 3   EUCTR2017-002370-39-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002026-36-IT   Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-IT   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
   Alexion Pharmaceuticals
      2015   Phase 1/Phase 2   NCT02598583   Australia;Korea, Republic of
   Alexion Pharmaceuticals Inc.
      2020   Phase 4   EUCTR2019-003440-74-GB   United Kingdom
   Alexion Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2017-002820-26-NO   France;Netherlands;Norway;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002820-26-NL   France;Netherlands;Norway;Russian Federation;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002820-26-GB   France;Netherlands;Norway;Russian Federation;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002026-36-NL   Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002026-36-GB   Germany;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002026-36-ES   Germany;Spain;United States
      2017   Phase 3   EUCTR2016-002026-36-DE   Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-PT   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-NL   Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-FI   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-ES   Austria;Denmark;Germany;Korea, Republic of;Spain;United States
      2017   Phase 3   EUCTR2016-002025-11-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-CZ   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States Minor Outlying Islands
      2017   Phase 3   EUCTR2016-002025-11-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002025-11-SE   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002025-11-GB   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002025-11-DK   Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002025-11-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2017-002820-26-FR   France;Netherlands;United States
   Alexion Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2017-002370-39-SE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-NL   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-GB   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-FI   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-ES   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-DE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-CZ   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-BE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-AT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002370-39-FR   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2015-002674-20-SE   Canada;Finland;France;Germany;Russian Federation;Spain;Sweden;Taiwan;United Kingdom
      2015   Phase 2   EUCTR2015-002674-20-GB   Canada;Finland;France;Germany;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
      2015   Phase 2   EUCTR2015-002674-20-ES   Canada;Finland;France;Germany;Russian Federation;Spain;Sweden;Taiwan;United Kingdom
      2015   Phase 2   EUCTR2015-002674-20-DE   Canada;Finland;France;Germany;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
   Aurand Lisa
      2023   Phase 3   JPRN-jRCT2031220440   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;South Korea;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
ALXN2040
   ALEXION PHARMACEUTICALS INCORPORATED
      2022   Phase 3   EUCTR2021-004253-22-IT   Argentina;Brazil;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003829-18-IT   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States
   Alexion Pharmaceuticals Inc.
      2023   Phase 3   EUCTR2021-004253-22-PL   Brazil;Canada;Czechia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Poland;Spain;Thailand;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004253-22-GR   Brazil;Canada;Czechia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Poland;Spain;Thailand;United Kingdom;United States
      2022   Phase 3   EUCTR2021-004253-22-FR   Argentina;Brazil;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003829-18-GR   Argentina;Brazil;Canada;Colombia;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003829-18-PL   Argentina;Brazil;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003829-18-NL   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003829-18-DE   Brazil;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003829-18-GB   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003829-18-FR   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2018   Phase 2   EUCTR2016-003526-16-GB   Italy;United Kingdom;United States
   Kamata Takeo
      2021   Phase 3   JPRN-jRCT2021210014   America;Japan
ALXN2050
   Achillion Pharmaceuticals, Inc., a wholly owned subsidiary of Alexion Pharmaceuticals Inc.
      2021   Phase 2   EUCTR2019-003830-17-IT   Italy;Korea, Republic of;New Zealand;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003830-17-GB   Italy;Korea, Republic of;New Zealand;United Kingdom;United States
   Alexion Pharmaceuticals Inc.
      2021   Phase 2   EUCTR2019-003830-17-ES   Canada;France;Germany;Italy;Korea, Republic of;New Zealand;Spain;Turkey;United Kingdom
   Alexion Pharmaceuticals, Inc.
      2019   Phase 2   NCT04170023   Canada;Germany;Italy;Korea, Republic of;New Zealand;Spain;Turkey;United Kingdom;United States
Anti haemophilus influeanze vaccination
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2016-003526-16-IT   Italy;Korea, Republic of;New Zealand;United Kingdom;United States
ANTI-C5 antibody
   ALEXION PHARMACEUTICALS INCORPORATED
      2006   -   EUCTR2005-000043-28-ES   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-000043-28-SE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-000043-28-IE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   Phase 3   EUCTR2005-000043-28-GB   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-000043-28-DE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   -   EUCTR2004-002795-42-SE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-002795-42-IE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-002795-42-GB   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-002795-42-ES   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   -   EUCTR2004-002795-42-DE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2004   -   EUCTR2004-000646-20-SE   Ireland;Italy;Sweden
      2004   Phase 3   EUCTR2004-000646-20-IE   Ireland;Italy;Sweden;United Kingdom
      2004   Phase 3   EUCTR2004-000646-20-GB   Ireland;Italy;Sweden;United Kingdom
   ALEXION PHARMACEUTICALS, INC.
      -   -   EUCTR2009-010402-11-Outside-EU/EEA   United States
   Suzuki Kazuyuki
      2021   Phase 3   JPRN-jRCT2051200132   Japan;Netherlands
ANTI-thymocyte globulin
   Roswell Park Cancer Institute
      2009   -   NCT00856388   United States
APL-2
   Apellis Pharmaceuticals
      2018   Phase 2   EUCTR2017-005140-16-GR   Bulgaria;Greece;Poland;Romania;Serbia
      2018   Phase 2   EUCTR2017-005140-16-BG   Bulgaria;Greece;Poland;Romania;Serbia
   Apellis Pharmaceuticals, Inc.
      2020   Phase 3   EUCTR2019-001106-23-FR   Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001106-23-ES   Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States
      2019   Phase 3   NCT04085601   Colombia;Hong Kong;Malaysia;Mexico;Peru;Philippines;Poland;Serbia;Singapore;Thailand
      2019   Phase 3   EUCTR2019-001106-23-GB   Australia;Bulgaria;Canada;France;Hong Kong;Japan;Korea, Republic of;Malaysia;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004220-11-PL   Argentina;Brazil;Colombia;Hong Kong;Hungary;Malaysia;Mexico;Peru;Philippines;Poland;Serbia;Thailand
      2019   Phase 3   EUCTR2017-004268-36-NL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004268-36-IT   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004268-36-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2018   Phase 2   NCT03593200   Bulgaria;Greece;Poland;Romania;Serbia
      2018   Phase 3   NCT03500549   Australia;Belgium;Canada;France;Germany;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004268-36-FR   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004268-36-ES   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004268-36-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004268-36-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2015   Phase 1   NCT02588833   Hong Kong;Malaysia;New Zealand;Thailand
      2015   Phase 1   NCT02264639   United States
      -   Phase 3   EUCTR2019-001106-23-DE   Australia;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States
   Machaidze Zurab
      2022   Phase 3   JPRN-jRCT2031210645   Australia;Belgium;Canada;France;Germany;Japan;Korea;Russia;Spain;the U.S.;the United Kingdom
   Uchendu Uchendu
      2019   Phase 3   JPRN-jRCT2031220046   Australia;Belgium;Bulgaria;Canada;Colombia;France;Germany;Hong Kong;Italy;Japan;Malaysia;Mexico;Peru;Philippines;Russia;Serbia;Singapore;South Korea;Spain;Thailand;the Netherlands;the United Kingdom;the United States
Aspaveli
   Apellis Pharmaceuticals, Inc.
      2022   Phase 2   EUCTR2020-001350-21-NL   Australia;Czech Republic;Czechia;France;Germany;Hungary;Ireland;Italy;Malaysia;Netherlands;Poland;Romania;Serbia;Spain;Thailand;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001350-21-CZ   Australia;Czech Republic;Czechia;France;Germany;Hungary;Ireland;Italy;Malaysia;Netherlands;Poland;Romania;Serbia;Spain;Thailand;United Kingdom;United States
      -   Phase 3   EUCTR2019-001106-23-DE   Australia;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States
BCD-148
   Biocad
      2019   Phase 3   NCT04060264   Russian Federation
BCX10013
   BioCryst Pharmaceuticals
      2023   Phase 1   NCT06100900   Malaysia;South Africa
BCX9930
   BioCryst Pharmaceuticals
      2023   Phase 2   NCT05741346   France;Hungary;Korea, Republic of;Malaysia;South Africa;Spain;United Kingdom
      2021   Phase 2   NCT05116774   France;Hungary;Italy;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   NCT04702568   Austria;South Africa;United Kingdom
      2020   Phase 1/Phase 2   NCT04330534   Austria;South Africa;United Kingdom
   BioCryst Pharmaceuticals Inc
      2023   Phase 2   EUCTR2021-006776-17-HU   France;Hungary;Korea, Republic of;Malaysia;South Africa;Spain;United Kingdom
      2023   Phase 2   EUCTR2021-006776-17-FR   Argentina;Austria;Azerbaijan;Brazil;Canada;China;Colombia;Czechia;France;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Romania;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2020-004403-14-CZ   Albania;Argentina;Azerbaijan;Brazil;Canada;China;Czech Republic;Czechia;Italy;Lithuania;Poland;Romania;Serbia;South Africa;Spain;Sweden;Turkey;United States
      2021   Phase 2   EUCTR2020-004403-14-LT   Albania;Argentina;Azerbaijan;Brazil;Canada;China;Czech Republic;European Union;Italy;Lithuania;Serbia;South Africa;Spain;Turkey;United States
      2021   Phase 2   EUCTR2020-004403-14-ES   Albania;Argentina;Azerbaijan;Brazil;Canada;China;Czech Republic;European Union;Italy;Lithuania;Serbia;South Africa;Spain;Turkey;United States
   Sakagami Yohei
      2022   Phase 2   JPRN-jRCT2051210179   Argentina;Austria;Brazil;Canada;Colombia;France;Hong Kong;Hungary;Italy;Japan;Netherlands;Slovakia;South Korea;Spain;Taiwan;Turkey;United Kingdom;United States
BCX9930 hydrochloride
   BIOCRYST PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-004438-39-IT   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004403-14-IT   Albania;Argentina;Azerbaijan;Brazil;Canada;China;European Union;Italy;Lithuania;Serbia;South Africa;Spain;Turkey;United States
      2020   Phase 2   EUCTR2020-000501-93-IT   Austria;Denmark;European Union;Italy;South Africa;United Kingdom
   BioCryst Pharmaceuticals Inc
      2022   Phase 2   EUCTR2020-004438-39-NL   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-SK   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-HU   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-FR   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-ES   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2020-000501-93-GB   European Union;South Africa;United Kingdom
      2020   Phase 2   EUCTR2020-000501-93-DK   Austria;Denmark;European Union;Italy;South Africa;United Kingdom
      2020   Phase 2   EUCTR2020-000501-93-AT   Austria;Denmark;European Union;Italy;South Africa;United Kingdom
BCX9930 monotherapy
   BioCryst Pharmaceuticals
      2021   Phase 2   NCT05116787   Korea, Republic of;Malaysia;South Africa;Spain;Taiwan;United States
Benzilpenicillina benzatinica
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-000888-33-IT   France;Germany;Italy
Bexsero
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-000665-79-IT   Italy;Korea, Republic of;New Zealand;United Kingdom
      2018   Phase 2   EUCTR2016-003526-16-IT   Italy;Korea, Republic of;New Zealand;United Kingdom;United States
Bexsero - sospensione iniettabile - USO intramuscolare - siringa P
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004385-19-IT   Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States
Bexsero - sospensione iniettabile - USO intramuscolare - siringa preriempita (vetro) - 0.5ML - 1 siringa preriempita CON AGO
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-000888-33-IT   France;Germany;Italy
Bexsero sospensione iniettabile IN siringa preriempita
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-000888-33-IT   France;Germany;Italy
Bexsero – sospensione iniettabile – siringa preriempita
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-003172-41-IT   China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States
Biospecimen collection
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Bone marrow aspiration
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Bone marrow biopsy
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Bryostatin 1
   National Cancer Institute (NCI)
      2001   Phase 1   NCT00012376   United States
C5 INH MAB, SKY59, RO/CH7092230
   F. HOFFMANN - LA ROCHE LTD.
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-IT   Brazil;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand
   F. Hoffmann-La Roche Ltd
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-HU   Brazil;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-FR   France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-DE   France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands
      2016   Phase 1;Phase 2   EUCTR2016-002128-10-NL   Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;United Kingdom
C5 inhibitor
   Alexion Pharmaceuticals, Inc.
      2020   Phase 3   NCT04469465   Brazil;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;United Kingdom;United States
   Sakagami Yohei
      2022   Phase 2   JPRN-jRCT2051210179   Argentina;Austria;Brazil;Canada;Colombia;France;Hong Kong;Hungary;Italy;Japan;Netherlands;Slovakia;South Korea;Spain;Taiwan;Turkey;United Kingdom;United States
Campath, chemo and/or TBI allo SCT
   David Rizzieri, MD
      1999   Phase 2   NCT00004143   United States
Carbon-14 labeled HSK39297
   Haisco Pharmaceutical Group Co., Ltd.
      2024   Phase 1   NCT06852092   China
Cell infusion
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
Cemdisiran
   Aurand Lisa
      2024   Phase 3   JPRN-jRCT2031230013   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;South Korea;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2023   Phase 3   JPRN-jRCT2031240002   Brazil;China;France;Germany;Greece;Hungary;India;Italy;Japan;Malaysia;Mexico;Philippines;Poland;Romania;Singapore;South Korea;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2023   Phase 3   JPRN-jRCT2031220440   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;South Korea;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   REGENERON PHARMACEUTICALS, INC.
      2022   Phase 3   EUCTR2021-004931-10-IT   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-IT   Brazil;Canada;China;Colombia;France;Greece;Hungary;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Singapore;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
   Regeneron Pharmaceuticals
      2023   -   NCT06028594   -
      2023   Phase 3   NCT05744921   Canada;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom
      2022   Phase 3   NCT05133531   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   NCT05131204   United States
      2021   Phase 2   NCT04888507   United Kingdom
      2021   Phase 2   NCT04811716   Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom
   Regeneron Pharmaceuticals, Inc.
      2023   Phase 3   EUCTR2021-004931-10-RO   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004931-10-PL   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004931-10-HU   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004931-10-GR   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-RO   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-PL   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-HU   Brazil;Canada;China;Colombia;France;Greece;Hungary;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-GR   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-ES   Brazil;Canada;China;Colombia;France;Greece;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Singapore;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-PL   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-GR   Brazil;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-FR   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-ES   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-DE   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-005005-17-HU   Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom
Computed tomography
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Coversin
   AKARI Therapeutics
      2018   Phase 2   NCT03427060   Argentina;United States
      2016   Phase 2   NCT02591862   Netherlands
   Akari Therapeutics Plc
      2019   Phase 3   EUCTR2016-004129-18-LT   Argentina;France;Germany;India;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom
      2018   Phase 3   EUCTR2016-004129-18-NL   Argentina;Lithuania;Netherlands;Poland;United Kingdom
      2017   Phase 3   EUCTR2016-004129-18-PL   Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom
      2016   Phase 2   EUCTR2016-002067-33-GB   United Kingdom
   Volution Immuno Pharmaceuticals (UK) Ltd
      2016   Phase 2   EUCTR2015-003778-34-NL   Netherlands
Crovalimab
   CHUGAI PHARMACEUTICAL CO., LTD.
      2017   Phase 1-2   JPRN-jRCT2080223462   Asia except Japan;Europe;Japan
   Chugai Pharmaceutical Co., Ltd.
      2020   Phase 3   JPRN-jRCT2080225334   Asia except Japan;Europe;Japan;North America;Oceania;South America
      2020   Phase 3   JPRN-jRCT2080225329   Africa;Asia except Japan;Europe;Japan;North America;Oceania;South America
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2020-000597-26-IT   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-IT   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
   F. Hoffman-La Roche Ltd.
      2022   Phase 3   EUCTR2019-004931-21-RO   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-FR   Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-PL   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-HU   Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-DE   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      -   Phase 3   EUCTR2019-004931-21-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-000597-26-PT   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-IE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-FR   Australia;Belgium;Brazil;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-EE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-CZ   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-BE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-PL   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-HU   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-GR   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-DE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      -   Phase 3   EUCTR2020-000597-26-SE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
   Hoffmann-La Roche
      2021   Phase 3   NCT04654468   China
      2020   Phase 3   NCT04434092   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   NCT04432584   Australia;Belgium;Brazil;Canada;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Saudi Arabia;Singapore;Slovakia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2016   Phase 1/Phase 2   NCT03157635   France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands
Cyclophosphamide
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2019   Phase 2   NCT03520647   United States
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      1996   Phase 2   NCT00004464   United States
Cyclosporine
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00397813   Denmark;Germany;Italy;United States
Cytoreductive regimen followed BY A CD34+E- selected allogeneic stem cell transplant
   Memorial Sloan Kettering Cancer Center
      2001   Phase 2   NCT00587054   United States
Danicopan
   ALEXION PHARMACEUTICALS INCORPORATED
      2022   Phase 3   EUCTR2021-004253-22-IT   Argentina;Brazil;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003829-18-IT   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States
   Alexion Pharmaceuticals
      2018   Phase 2   NCT03472885   Italy;United Kingdom;United States
   Alexion Pharmaceuticals Inc.
      2023   Phase 3   EUCTR2021-004253-22-PL   Brazil;Canada;Czechia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Poland;Spain;Thailand;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004253-22-GR   Brazil;Canada;Czechia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Poland;Spain;Thailand;United Kingdom;United States
      2022   Phase 3   EUCTR2021-004253-22-FR   Argentina;Brazil;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003829-18-GR   Argentina;Brazil;Canada;Colombia;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003829-18-PL   Argentina;Brazil;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003829-18-NL   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003829-18-DE   Brazil;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003829-18-GB   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003829-18-FR   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2018   Phase 2   EUCTR2016-003526-16-GB   Italy;United Kingdom;United States
   Alexion Pharmaceuticals, Inc.
      2025   Phase 3   NCT06449001   France
      2023   -   NCT05982938   -
      2022   Phase 3   NCT05389449   Brazil;Canada;Czechia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Poland;Spain;Thailand;United Kingdom;United States
      2020   Phase 3   NCT04469465   Brazil;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;United Kingdom;United States
   Kamata Takeo
      2021   Phase 3   JPRN-jRCT2021210014   America;Japan
   Sugita Yuko
      2023   Phase 3   JPRN-jRCT2031230248   Italy;Japan;United Kingdom;United States
Echocardiography
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Eculizumab
   ALEXION PHARMACEUTICALS INC
      2005   -   EUCTR2005-000043-28-IT   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   -   EUCTR2004-002795-42-IT   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2004   -   EUCTR2004-000646-20-IT   Ireland;Italy;Sweden
   ALEXION PHARMACEUTICALS INCORPORATED
      2017   Phase 3   EUCTR2016-002026-36-IT   Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-IT   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2006   -   EUCTR2005-000043-28-ES   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-000043-28-SE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-000043-28-IE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   Phase 3   EUCTR2005-000043-28-GB   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-000043-28-DE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   -   EUCTR2004-002795-42-SE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-002795-42-IE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-002795-42-GB   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-002795-42-ES   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   -   EUCTR2004-002795-42-DE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2004   -   EUCTR2004-000646-20-SE   Ireland;Italy;Sweden
      2004   Phase 3   EUCTR2004-000646-20-IE   Ireland;Italy;Sweden;United Kingdom
      2004   Phase 3   EUCTR2004-000646-20-GB   Ireland;Italy;Sweden;United Kingdom
   ALEXION PHARMACEUTICALS, INC.
      -   -   EUCTR2009-010402-11-Outside-EU/EEA   United States
   AMGEN INC.
      2017   Phase 3   EUCTR2017-001418-27-IT   Czech Republic;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States
   Alexion Pharmaceuticals
      2021   Phase 4   NCT04320602   United Kingdom
      2018   Phase 2   NCT03472885   Italy;United Kingdom;United States
      2016   Phase 3   NCT02946463   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czechia;Estonia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2009   Phase 4   NCT00867932   United States
      2008   Phase 2   NCT01194804   -
      2007   Phase 2   NCT01192399   -
      2007   Phase 3   NCT00438789   United States
      2005   Phase 3   NCT00122317   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2004   Phase 3   NCT00122330   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Sweden;Switzerland;United Kingdom;United States
      2004   Phase 3   NCT00122304   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
   Alexion Pharmaceuticals Incorporated
      2017   Phase 3   EUCTR2016-002026-36-NL   Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002026-36-GB   Germany;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002026-36-ES   Germany;Spain;United States
      2017   Phase 3   EUCTR2016-002026-36-DE   Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-PT   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-NL   Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-FI   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-ES   Austria;Denmark;Germany;Korea, Republic of;Spain;United States
      2017   Phase 3   EUCTR2016-002025-11-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-CZ   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States Minor Outlying Islands
      2017   Phase 3   EUCTR2016-002025-11-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002025-11-SE   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002025-11-GB   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002025-11-DK   Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002025-11-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
   Alexion Pharmaceuticals, Inc.
      2023   Phase 3   NCT05886244   China
      2017   Phase 3   NCT03056040   Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States
   Amgen
      2019   Phase 3   NCT03818607   Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Apellis Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2017-004268-36-NL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004268-36-IT   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004268-36-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004268-36-FR   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004268-36-ES   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004268-36-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004268-36-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
   Aurand Lisa
      2023   Phase 3   JPRN-jRCT2031240002   Brazil;China;France;Germany;Greece;Hungary;India;Italy;Japan;Malaysia;Mexico;Philippines;Poland;Romania;Singapore;South Korea;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2023   Phase 3   JPRN-jRCT2031220440   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;South Korea;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   BIOCRYST PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-004438-39-IT   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States
   BioCryst Pharmaceuticals
      2021   Phase 2   NCT05116774   France;Hungary;Italy;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   NCT04702568   Austria;South Africa;United Kingdom
   BioCryst Pharmaceuticals Inc
      2022   Phase 2   EUCTR2020-004438-39-NL   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-SK   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-HU   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-FR   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-ES   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States
   Biocad
      2020   Phase 3   NCT06987864   Russian Federation
   Chugai Pharmaceutical Co., Ltd.
      2020   Phase 3   JPRN-jRCT2080225334   Asia except Japan;Europe;Japan;North America;Oceania;South America
      2020   Phase 3   JPRN-jRCT2080225329   Africa;Asia except Japan;Europe;Japan;North America;Oceania;South America
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2020-000597-26-IT   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-IT   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
   F. Hoffman-La Roche Ltd.
      2022   Phase 3   EUCTR2019-004931-21-RO   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-FR   Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-PL   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-HU   Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-DE   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      -   Phase 3   EUCTR2019-004931-21-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-000597-26-PT   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-IE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-FR   Australia;Belgium;Brazil;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-EE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-CZ   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-BE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-PL   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-HU   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-GR   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-DE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      -   Phase 3   EUCTR2020-000597-26-SE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
   Hoffmann-La Roche
      2020   Phase 3   NCT04434092   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   NCT04432584   Australia;Belgium;Brazil;Canada;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Saudi Arabia;Singapore;Slovakia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Jonsson Comprehensive Cancer Center
      2004   Phase 3   NCT00112983   United States
   NOVARTIS PHARMA AG
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2005   Phase 3   NCT00130000   United States
      2004   Phase 3   NCT00098280   United States
   Novartis Pharma AG
      2021   Phase 3   EUCTR2019-004665-40-DE   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004665-40-CZ   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-NL   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-HU   Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-FR   Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
   Novartis Pharmaceuticals
      2021   Phase 3   NCT04558918   Brazil;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
   Regeneron Pharmaceuticals
      2022   Phase 3   NCT05133531   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   NCT05131204   United States
   Regeneron Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-004486-40-RO   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-PL   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-GR   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-PL   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-GR   Brazil;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-FR   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-ES   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-DE   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
   Roche Farma S. A. U. que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche Ltd
      2019   Phase 4   EUCTR2019-001453-10-ES   Argentina;Brazil;Canada;Colombia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Sakagami Yohei
      2022   Phase 2   JPRN-jRCT2051210179   Argentina;Austria;Brazil;Canada;Colombia;France;Hong Kong;Hungary;Italy;Japan;Netherlands;Slovakia;South Korea;Spain;Taiwan;Turkey;United Kingdom;United States
   Samsung Bioepis Co., Ltd.
      2019   Phase 3   NCT04058158   India;Korea, Republic of;Malaysia;Mexico;Romania;Taiwan;Thailand;Ukraine
   Suzuki Kazuyuki
      2021   Phase 3   JPRN-jRCT2051200132   Japan;Netherlands
   West China Hospitai,Sichuan University
      2023   -   ChiCTR2300067949   China
Eculizumab injection
   Chengdu Suncadia Medicine Co., Ltd.
      2024   Phase 3   NCT06593938   China
   Haisco Pharmaceutical Group Co., Ltd.
      2025   Phase 3   NCT06799546   China
   Wuhan Createrna Science and Technology Co., Ltd
      2024   Phase 3   NCT06932744   China
FC- and CDR-modified humanised monoclonal antibody against C5
   Alexion Pharmaceuticals Incorporated
      2017   Phase 3   EUCTR2016-002026-36-NL   Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002026-36-GB   Germany;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002026-36-ES   Germany;Spain;United States
      2017   Phase 3   EUCTR2016-002026-36-DE   Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-PT   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-NL   Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-FI   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-ES   Austria;Denmark;Germany;Korea, Republic of;Spain;United States
      2017   Phase 3   EUCTR2016-002025-11-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-CZ   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States Minor Outlying Islands
      2017   Phase 3   EUCTR2016-002025-11-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002025-11-SE   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002025-11-GB   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002025-11-DK   Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002025-11-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
   Alexion Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2017-002370-39-NL   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-GB   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-ES   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-DE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-CZ   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-BE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-AT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002370-39-FR   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
Filgrastim
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      1996   Phase 2   NCT00004464   United States
Fludarabine
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
Fludarabine phosphate
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00397813   Denmark;Germany;Italy;United States
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
      2012   Phase 2   NCT01529827   United States
      2009   -   NCT00856388   United States
G-CSF
   Tianjin Medical University General Hospital
      2014   -   ChiCTR-ONC-13003994   China
Gelatin
   Yamauchi Kyosuke
      2021   Phase 3   JPRN-jRCT2021210059   Inited Kingdom;Italy;Japan;Republic of Korea;Taiwan;United State
H5g1.1-MAB
   ALEXION PHARMACEUTICALS INC
      2005   -   EUCTR2005-000043-28-IT   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
   ALEXION PHARMACEUTICALS INCORPORATED
      2006   -   EUCTR2005-000043-28-ES   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-000043-28-SE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-000043-28-IE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   Phase 3   EUCTR2005-000043-28-GB   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-000043-28-DE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   -   EUCTR2004-002795-42-SE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-002795-42-IE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-002795-42-GB   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-002795-42-ES   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2005   -   EUCTR2004-002795-42-DE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
      2004   -   EUCTR2004-000646-20-SE   Ireland;Italy;Sweden
      2004   Phase 3   EUCTR2004-000646-20-IE   Ireland;Italy;Sweden;United Kingdom
      2004   Phase 3   EUCTR2004-000646-20-GB   Ireland;Italy;Sweden;United Kingdom
   ALEXION PHARMACEUTICALS, INC.
      -   -   EUCTR2009-010402-11-Outside-EU/EEA   United States
Haemophilus influenzae
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004385-19-IT   Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
Hiberix - polvere E solvente PER soluzione iniettabile PER USO intramuscolare 1 flaconcino DI polvere + 1 siringa preriempita DI solvente DA 0.5 ML
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-003172-41-IT   China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States
HRS-5965 capsule
   Chengdu Suncadia Medicine Co., Ltd.
      2024   Phase 3   NCT06715943   China
      2024   Phase 3   NCT06593938   China
HRS-5965 capsules
   Chengdu Suncadia Medicine Co., Ltd.
      2024   Phase 1   NCT06490991   China
HRS-5965 tablets
   Chengdu Suncadia Medicine Co., Ltd.
      2024   Phase 1   NCT06490991   China
      2024   Phase 2   NCT06238544   China
      2023   Phase 2   NCT06051357   China
HSK39297
   Haisco Pharmaceutical Group Co., Ltd.
      2024   Phase 2   NCT06561841   China
HSK39297 tablets
   Haisco Pharmaceutical Group Co., Ltd.
      2025   Phase 3   NCT06799546   China
      2025   Phase 2   NCT06745622   China
Human monoclonal antibody directed against complement 5 protein
   Novartis Pharma Services AG
      2015   Phase 2   EUCTR2014-005338-74-LT   Czech Republic;Czechia;Japan;Lithuania
      2015   Phase 2   EUCTR2014-005338-74-CZ   Czech Republic;Czechia;Japan;Lithuania
Humanized ANTI-factor BB monoclonal antibody
   Sanofi
      2021   Phase 1   NCT06326814   United States
Iptacopan
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004385-19-IT   Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2021   Phase 3   EUCTR2020-004385-19-ES   Brazil;China;Japan;Korea, Republic of;Malaysia;Singapore;Spain;Taiwan;United States
   Novartis Pharma AG
      2022   Phase 3   EUCTR2020-004385-19-NL   Brazil;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004385-19-LT   Brazil;China;Czech Republic;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States
      2021   Phase 3   EUCTR2020-004385-19-FR   Brazil;China;Czech Republic;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States
      2021   Phase 3   EUCTR2020-004385-19-CZ   Brazil;China;Czech Republic;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States
      2021   Phase 3   EUCTR2020-003172-41-FR   China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003172-41-CZ   China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004665-40-DE   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-NL   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
   Novartis Pharma Services AG
      2015   Phase 2   EUCTR2014-005338-74-LT   Czech Republic;Czechia;Japan;Lithuania
      2015   Phase 2   EUCTR2014-005338-74-CZ   Czech Republic;Czechia;Japan;Lithuania
   Novartis Pharmaceuticals
      2025   -   NCT06903234   Switzerland
      2023   Phase 3   NCT05630001   France;Germany;Italy;Korea, Republic of;Spain;Turkey;United Kingdom;United States
      2021   -   NCT05222412   -
      2021   Phase 3   NCT04820530   China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom
      2021   Phase 3   NCT04747613   Brazil;China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 2   NCT03439839   France;Germany;Italy
Iron dextran
   Institute of Hematology and Blood Diseases Hospital,Chinese Academy of Medical Sciences
      2014   -   ChiCTR-TRC-14004219   China
Iron sucrose
   Institute of Hematology and Blood Diseases Hospital,Chinese Academy of Medical Sciences
      2014   -   ChiCTR-TRC-14004219   China
KP104
   Kira Pharmacenticals (US), LLC.
      2022   Phase 2   NCT05476887   China
      2020   Phase 1   NCT05490017   Australia
L04aa25
   ALEXION PHARMACEUTICALS INCORPORATED
      2005   -   EUCTR2005-000043-28-DE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom
Laboratory biomarker analysis
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00397813   Denmark;Germany;Italy;United States
   National Cancer Institute (NCI)
      2001   Phase 1   NCT00012376   United States
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
      2012   Phase 2   NCT01529827   United States
Lapine T-lymphocyte immune globulin
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Levamisole+cyclosporin A+glucocorticoids
   Institute of Hematology & Blood Diseases Hospital
      2013   Phase 2   NCT01760096   China
      2012   Phase 2   NCT01642979   China
LFG316
   Novartis Pharma Services AG
      2015   Phase 2   EUCTR2014-005338-74-LT   Czech Republic;Czechia;Japan;Lithuania
      2015   Phase 2   EUCTR2014-005338-74-CZ   Czech Republic;Czechia;Japan;Lithuania
   Novartis Pharmaceuticals
      2015   Phase 2   NCT02534909   Czech Republic;Czechia;Japan;Lithuania;Moldova, Republic of
LNP023
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-000888-33-IT   France;Germany;Italy
   Novartis Pharmaceuticals
      2025   Phase 3   NCT06934967   -
      2025   -   NCT06931691   -
      2021   Phase 3   NCT04820530   China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom
      2021   Phase 3   NCT04558918   Brazil;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   NCT03896152   Korea, Republic of;Malaysia;Russian Federation;Singapore;Taiwan
      2015   Phase 2   NCT02534909   Czech Republic;Czechia;Japan;Lithuania;Moldova, Republic of
   Suzuki Kazuyuki
      2021   Phase 3   JPRN-jRCT2051200132   Japan;Netherlands
LNP023 hydrochloride salt
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004385-19-IT   Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2021   Phase 3   EUCTR2020-004385-19-ES   Brazil;China;Japan;Korea, Republic of;Malaysia;Singapore;Spain;Taiwan;United States
   Novartis Pharma AG
      2022   Phase 3   EUCTR2020-004385-19-NL   Brazil;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004385-19-LT   Brazil;China;Czech Republic;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States
      2021   Phase 3   EUCTR2020-004385-19-FR   Brazil;China;Czech Republic;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States
      2021   Phase 3   EUCTR2020-004385-19-CZ   Brazil;China;Czech Republic;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States
      2021   Phase 3   EUCTR2020-003172-41-FR   China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003172-41-CZ   China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004665-40-DE   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004665-40-CZ   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-NL   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-HU   Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-FR   Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-000888-33-FR   France;Germany;Italy
      2018   Phase 2   EUCTR2017-000888-33-DE   France;Germany;Italy
   Novartis Pharma Services AG
      2015   Phase 2   EUCTR2014-005338-74-LT   Czech Republic;Czechia;Japan;Lithuania
      2015   Phase 2   EUCTR2014-005338-74-CZ   Czech Republic;Czechia;Japan;Lithuania
Melphalan
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States
      2009   -   NCT00856388   United States
Menveo
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-000665-79-IT   Italy;Korea, Republic of;New Zealand;United Kingdom
      2018   Phase 2   EUCTR2016-003526-16-IT   Italy;Korea, Republic of;New Zealand;United Kingdom;United States
Menveo - polv.E soluz.PER soluz. iniett.-USO intramuscolare-comp. coniug.liofilizz.mena:flac.(vetro) comp. goniug.liqui.mencwy:flac.(vetro)-1 flac+1flac
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004385-19-IT   Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States
      2018   Phase 2   EUCTR2017-000888-33-IT   France;Germany;Italy
Menveo polvere E soluzione PER soluzione iniettabile
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-000888-33-IT   France;Germany;Italy
Menveo – polvere E soluzione PER soluzione iniettabile
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-003172-41-IT   China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
Methotrexate
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States
Methylprednisolone
   Department of Hematology, Second Medical Center, Chinese PLA General Hospital
      2021   Phase 2   ChiCTR2000039675   Chinese
Miltenyi biotec clinimacs
   St. Jude Children's Research Hospital
      2003   Phase 2   NCT00145613   United States
Miltenyi clinimacs
   St. Jude Children's Research Hospital
      2005   Phase 2   NCT00143559   United States
Multigated acquisition scan
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
MY008211A tablets
   Wuhan Createrna Science and Technology Co., Ltd
      2024   Phase 2/Phase 3   NCT06933914   China
      2024   Phase 3   NCT06932744   China
      2024   Phase 3   NCT06932471   China
      2024   Phase 1   NCT06543459   China
      2024   Phase 2   NCT06134414   -
      2023   Phase 2   NCT06050226   China
      2023   Phase 1   NCT05828472   China
      2022   Phase 1   NCT05642585   China
Mycophenolate mofetil
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00397813   Denmark;Germany;Italy;United States
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States
Myeloablative preparative regimen
   Masonic Cancer Center, University of Minnesota
      2014   -   NCT02179359   United States
NM8074
   NovelMed Therapeutics
      2026   Phase 2   NCT05731050   -
      2026   Phase 2   NCT05646563   -
      2026   Phase 2   NCT05646524   -
Nonmyeloablative allogeneic hematopoietic stem cell transplantation
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00397813   Denmark;Germany;Italy;United States
NTQ5082
   Nanjing Chia-tai Tianqing Pharmaceutical
      2025   Phase 2   NCT06764303   China
OMS906 study drug
   Omeros Corporation
      2024   Phase 2   NCT06298955   Germany;Switzerland;Ukraine;United Kingdom
      2022   Phase 1   NCT05889299   Ukraine
OMS906 study drug - 3 MG/KG
   Omeros Corporation
      2023   Phase 2   NCT05972967   Germany;Greece;Switzerland;United Kingdom
OMS906 study drug - 5 MG/KG
   Omeros Corporation
      2023   Phase 2   NCT05972967   Germany;Greece;Switzerland;United Kingdom
Pegcetacoplan
   Apellis Pharmaceuticals, Inc.
      2022   Phase 2   EUCTR2020-001350-21-NL   Australia;Czech Republic;Czechia;France;Germany;Hungary;Ireland;Italy;Malaysia;Netherlands;Poland;Romania;Serbia;Spain;Thailand;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001350-21-CZ   Australia;Czech Republic;Czechia;France;Germany;Hungary;Ireland;Italy;Malaysia;Netherlands;Poland;Romania;Serbia;Spain;Thailand;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001106-23-FR   Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001106-23-ES   Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001106-23-GB   Australia;Bulgaria;Canada;France;Hong Kong;Japan;Korea, Republic of;Malaysia;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001106-23-BG   Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004220-11-PL   Argentina;Brazil;Colombia;Hong Kong;Hungary;Malaysia;Mexico;Peru;Philippines;Poland;Serbia;Thailand
      2019   Phase 3   EUCTR2017-004268-36-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2018   Phase 3   NCT03531255   Australia;Belgium;Bulgaria;Canada;Colombia;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Russian Federation;Serbia;Singapore;Spain;Thailand;United Kingdom;United States
      -   Phase 3   EUCTR2019-001106-23-DE   Australia;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States
   Machaidze Zurab
      2022   Phase 3   JPRN-jRCT2031210645   Australia;Belgium;Canada;France;Germany;Japan;Korea;Russia;Spain;the U.S.;the United Kingdom
   Swedish Orphan Biovitrum
      2023   -   NCT05776472   Australia;Belgium;Canada;Czechia;Finland;France;Germany;Greece;Hungary;Italy;Poland;Saudi Arabia;Spain;United Kingdom
   Uchendu Uchendu
      2019   Phase 3   JPRN-jRCT2031220046   Australia;Belgium;Bulgaria;Canada;Colombia;France;Germany;Hong Kong;Italy;Japan;Malaysia;Mexico;Peru;Philippines;Russia;Serbia;Singapore;South Korea;Spain;Thailand;the Netherlands;the United Kingdom;the United States
Peripheral blood stem cell transplantation
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00397813   Denmark;Germany;Italy;United States
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
      2012   Phase 2   NCT01529827   United States
Peripheral blood stem cells
   National Heart, Lung, and Blood Institute (NHLBI)
      2019   Phase 2   NCT03520647   United States
Pharmacological study
   National Cancer Institute (NCI)
      2001   Phase 1   NCT00012376   United States
Pneumovax - 10 siringhe preriempite CON AGO DA 0.5 ML
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-000888-33-IT   France;Germany;Italy
Pneumovax – soluzione iniettabile IN siringa preriempita DA 0,5 ML
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004385-19-IT   Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States
      2021   Phase 3   EUCTR2020-003172-41-IT   China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
Polisaccaride dell'haemophilus influenzae DI tipo B coniugato CON LA proteina tetanica
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-000665-79-IT   Italy;Korea, Republic of;New Zealand;United Kingdom
POST-transplant G-CSF
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
Pozelimab
   Aurand Lisa
      2024   Phase 3   JPRN-jRCT2031230013   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;South Korea;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2023   Phase 3   JPRN-jRCT2031240002   Brazil;China;France;Germany;Greece;Hungary;India;Italy;Japan;Malaysia;Mexico;Philippines;Poland;Romania;Singapore;South Korea;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2023   Phase 3   JPRN-jRCT2031220440   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;South Korea;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   REGENERON PHARMACEUTICALS, INC.
      2022   Phase 3   EUCTR2021-004931-10-IT   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-IT   Brazil;Canada;China;Colombia;France;Greece;Hungary;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Singapore;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
   Regeneron Pharmaceuticals
      2023   -   NCT06028594   -
      2023   Phase 3   NCT05744921   Canada;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom
      2022   Phase 3   NCT05133531   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   NCT05131204   United States
      2021   Phase 2   NCT04888507   United Kingdom
      2021   Phase 2   NCT04811716   Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom
   Regeneron Pharmaceuticals, Inc.
      2023   Phase 3   EUCTR2021-004931-10-RO   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004931-10-PL   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004931-10-HU   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004931-10-GR   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-RO   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-PL   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-HU   Brazil;Canada;China;Colombia;France;Greece;Hungary;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-GR   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-ES   Brazil;Canada;China;Colombia;France;Greece;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Singapore;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-PL   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-GR   Brazil;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-FR   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-ES   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-DE   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-005005-17-HU   Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom
Prevenar 13 - 0.5 ML sospension
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2016-003526-16-IT   Italy;Korea, Republic of;New Zealand;United Kingdom;United States
Quality-OF-life assessment
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
RA101495
   Ra Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-003956-19-FI   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Finland;Georgia;Germany;Hong Kong;Italy;Korea, Republic of;Malaysia;Mexico;New Zealand;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 2   NCT03225287   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003523-34-FI   Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States
RA101495 sodium
   Ra Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2016-003523-34-HU   Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003523-34-GB   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003523-34-DK   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003522-16-HU   Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom
      2017   Phase 2   EUCTR2016-003522-16-GB   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom
      2017   Phase 2   EUCTR2016-003522-16-FI   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom
      2017   Phase 2   EUCTR2016-003522-16-DK   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom
Rabbit ATG
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
Ravulizumab
   ALEXION PHARMACEUTICALS INCORPORATED
      2019   Phase 3   EUCTR2017-002370-39-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Alexion Pharmaceuticals
      2021   Phase 4   NCT04320602   United Kingdom
      2018   Phase 3   NCT03406507   France;Netherlands;Norway;Russian Federation;United Kingdom;United States
      2016   Phase 3   NCT02946463   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czechia;Estonia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2016   Phase 2   NCT02605993   Canada;France;Germany;Korea, Republic of;Spain;Sweden;Taiwan;United Kingdom
   Alexion Pharmaceuticals Inc.
      2020   Phase 4   EUCTR2019-003440-74-GB   United Kingdom
   Alexion Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2017-002820-26-NL   France;Netherlands;Norway;Russian Federation;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002820-26-GB   France;Netherlands;Norway;Russian Federation;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002026-36-NL   Germany;Italy;Netherlands;Spain;United Kingdom;United States
   Alexion Pharmaceuticals, Inc.
      2024   Phase 3   NCT06578949   China
      2022   -   NCT05274633   Italy
      2019   Phase 3   EUCTR2017-002370-39-SE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-NL   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-GB   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-FI   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-ES   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-DE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-CZ   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-BE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002370-39-AT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002370-39-FR   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2017   Phase 3   NCT03056040   Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States
   AstraZeneca
      2025   -   NCT06633536   Poland
   Aurand Lisa
      2023   Phase 3   JPRN-jRCT2031240002   Brazil;China;France;Germany;Greece;Hungary;India;Italy;Japan;Malaysia;Mexico;Philippines;Poland;Romania;Singapore;South Korea;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2023   Phase 3   JPRN-jRCT2031220440   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;South Korea;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   BIOCRYST PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-004438-39-IT   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States
   BioCryst Pharmaceuticals
      2021   Phase 2   NCT05116774   France;Hungary;Italy;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   NCT04702568   Austria;South Africa;United Kingdom
   BioCryst Pharmaceuticals Inc
      2022   Phase 2   EUCTR2020-004438-39-NL   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-SK   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-HU   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-FR   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-ES   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States
   Novartis Pharma AG
      2021   Phase 3   EUCTR2019-004665-40-DE   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004665-40-CZ   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-NL   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-HU   Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
   Novartis Pharmaceuticals
      2021   Phase 3   NCT04558918   Brazil;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
   Omeros Corporation
      2023   Phase 2   NCT05972967   Germany;Greece;Switzerland;United Kingdom
   REGENERON PHARMACEUTICALS, INC.
      2022   Phase 3   EUCTR2020-004486-40-IT   Brazil;Canada;China;Colombia;France;Greece;Hungary;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Singapore;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
   Regeneron Pharmaceuticals
      2022   Phase 3   NCT05133531   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   NCT05131204   United States
   Regeneron Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-004486-40-RO   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-PL   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-HU   Brazil;Canada;China;Colombia;France;Greece;Hungary;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-GR   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-ES   Brazil;Canada;China;Colombia;France;Greece;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Singapore;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-PL   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-GR   Brazil;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-FR   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-ES   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-DE   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
   Roche Farma S. A. U. que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche Ltd
      2019   Phase 4   EUCTR2019-001453-10-ES   Argentina;Brazil;Canada;Colombia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Sakagami Yohei
      2022   Phase 2   JPRN-jRCT2051210179   Argentina;Austria;Brazil;Canada;Colombia;France;Hong Kong;Hungary;Italy;Japan;Netherlands;Slovakia;South Korea;Spain;Taiwan;Turkey;United Kingdom;United States
   Suzuki Kazuyuki
      2021   Phase 3   JPRN-jRCT2051200132   Japan;Netherlands
Ravulizumab obds
   Alexion Pharmaceuticals, Inc.
      2019   Phase 3   NCT03748823   Australia;Austria;Belgium;Brazil;Canada;Finland;France;Italy;Netherlands;Russian Federation;Spain;Sweden;Turkey;United States
Reduced intensity preparative regimen
   Masonic Cancer Center, University of Minnesota
      2014   -   NCT02179359   United States
Reduced toxicity ablative regimen
   Masonic Cancer Center, University of Minnesota
      2014   -   NCT02179359   United States
REGN3918
   Aurand Lisa
      2024   Phase 3   JPRN-jRCT2031230013   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;South Korea;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2023   Phase 3   JPRN-jRCT2031220440   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;South Korea;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   REGENERON PHARMACEUTICALS, INC.
      2022   Phase 3   EUCTR2021-004931-10-IT   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-IT   Brazil;Canada;China;Colombia;France;Greece;Hungary;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Singapore;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2019-000130-20-IT   Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002734-20-IT   Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States
   Regeneron Pharmaceuticals
      2019   Phase 3   NCT04162470   Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom
      2019   Phase 2   NCT03946748   Hong Kong;Hungary;Korea, Republic of;Malaysia;United Kingdom
   Regeneron Pharmaceuticals, Inc.
      2023   Phase 3   EUCTR2021-004931-10-RO   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004931-10-PL   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004931-10-HU   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2023   Phase 3   EUCTR2021-004931-10-GR   Brazil;Canada;China;Colombia;France;Germany;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Democratic People's Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-RO   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-PL   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-HU   Brazil;Canada;China;Colombia;France;Greece;Hungary;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-GR   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-ES   Brazil;Canada;China;Colombia;France;Greece;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Singapore;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-PL   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-GR   Brazil;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-FR   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-ES   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-DE   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-005005-17-HU   Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom
      2020   Phase 3   EUCTR2019-000130-20-NL   Canada;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-000130-20-HU   Canada;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-000130-20-GB   Canada;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-000130-20-CZ   Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2018-002734-20-CZ   Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002734-20-NL   Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002734-20-HU   Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002734-20-GB   Canada;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States
Rituximab
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
RO7112689
   CHUGAI PHARMACEUTICAL CO., LTD.
      2017   Phase 1-2   JPRN-jRCT2080223462   Asia except Japan;Europe;Japan
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2020-000597-26-IT   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-IT   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
   F. Hoffman-La Roche Ltd.
      2021   Phase 3   EUCTR2019-004931-21-FR   Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-HU   Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-000597-26-FR   Australia;Belgium;Brazil;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-HU   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
RO7112689/F01
   F. HOFFMANN - LA ROCHE LTD.
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-IT   Brazil;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand
   F. Hoffmann-La Roche Ltd
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-HU   Brazil;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-FR   France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-DE   France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands
      2016   Phase 1;Phase 2   EUCTR2016-002128-10-NL   Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;United Kingdom
RO7112689/F03-01
   F. Hoffman-La Roche Ltd.
      2022   Phase 3   EUCTR2019-004931-21-RO   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-PL   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-DE   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
   F. Hoffmann-La Roche Ltd
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-DE   France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-000597-26-IE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-EE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-CZ   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-BE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-PL   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-GR   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-DE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      -   Phase 3   EUCTR2020-000597-26-SE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
RO7112689/F03-03
   F. Hoffmann-La Roche Ltd
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-DE   France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands
RO7112689/F03-10
   F. Hoffman-La Roche Ltd.
      2022   Phase 3   EUCTR2019-004931-21-RO   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-PL   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-DE   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      -   Phase 3   EUCTR2019-004931-21-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-000597-26-PT   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-IE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-EE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-CZ   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-BE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-PL   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-GR   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-DE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      -   Phase 3   EUCTR2020-000597-26-SE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
RVA576
   AKARI Therapeutics
      2018   Phase 3   NCT03588026   Kazakhstan;Lithuania;Sri Lanka
      2017   Phase 3   NCT03829449   Poland
   Akari Therapeutics Plc
      2019   Phase 3   EUCTR2016-004129-18-LT   Argentina;France;Germany;India;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom
      2018   Phase 3   EUCTR2016-004129-18-NL   Argentina;Lithuania;Netherlands;Poland;United Kingdom
      2017   Phase 3   EUCTR2016-004129-18-PL   Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom
      2017   Phase 3   EUCTR2016-004129-18-GB   Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom
      2016   Phase 2   EUCTR2016-002067-33-GB   United Kingdom
   Akari Therapeutics Plc.
      2018   Phase 3   EUCTR2017-003847-39-LT   Ecuador;Kazakhstan;Lithuania;Peru;Romania;Sri Lanka;Turkey
   Volution Immuno Pharmaceuticals (UK) Ltd
      2016   Phase 2   EUCTR2015-003778-34-NL   Netherlands
Sargramostim
   National Cancer Institute (NCI)
      2001   Phase 1   NCT00012376   United States
Sirolimus
   Peking Union Medical College Hospital
      2019   Phase 4   NCT03866681   China
Solaris
   BioCryst Pharmaceuticals Inc
      2022   Phase 2   EUCTR2020-004438-39-NL   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-SK   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-HU   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-FR   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-ES   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States
Soliris
   ALEXION PHARMACEUTICALS INCORPORATED
      2017   Phase 3   EUCTR2016-002026-36-IT   Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-IT   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
   ALEXION PHARMACEUTICALS, INC.
      -   -   EUCTR2009-010402-11-Outside-EU/EEA   United States
   AMGEN INC.
      2017   Phase 3   EUCTR2017-001418-27-IT   Czech Republic;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States
   AO GENERIUM
      2017   Phase 3   NCT04463056   Russian Federation
   Alexion Pharmaceuticals Incorporated
      2017   Phase 3   EUCTR2016-002026-36-NL   Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002026-36-GB   Germany;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002026-36-ES   Germany;Spain;United States
      2017   Phase 3   EUCTR2016-002026-36-DE   Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-PT   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-NL   Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-FI   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-ES   Austria;Denmark;Germany;Korea, Republic of;Spain;United States
      2017   Phase 3   EUCTR2016-002025-11-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-CZ   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States Minor Outlying Islands
      2017   Phase 3   EUCTR2016-002025-11-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002025-11-SE   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002025-11-GB   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002025-11-DK   Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002025-11-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
   Amgen Inc.
      2020   Phase 3   EUCTR2017-001418-27-SE   Brazil;Czech Republic;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2017-001418-27-PT   Czech Republic;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2017-001418-27-IE   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2017-001418-27-FI   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-001418-27-SI   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-001418-27-NO   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-001418-27-NL   Germany;Italy;Korea, Republic of;Netherlands;Norway;Spain;United Kingdom
      2019   Phase 3   EUCTR2017-001418-27-DE   Czech Republic;France;Germany;Ireland;Italy;Netherlands;Norway;Slovenia;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2017-001418-27-CZ   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-001418-27-GB   Germany;Italy;Netherlands;Norway;Spain;United Kingdom
      2017   Phase 3   EUCTR2017-001418-27-ES   Czech Republic;Finland;France;Germany;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Norway;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom
   Apellis Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2017-004268-36-NL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004268-36-IT   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2017-004268-36-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2018   Phase 3   NCT03500549   Australia;Belgium;Canada;France;Germany;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004268-36-FR   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004268-36-ES   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004268-36-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-004268-36-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
   Aurand Lisa
      2023   Phase 3   JPRN-jRCT2031220440   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;South Korea;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   BIOCRYST PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-004438-39-IT   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States
   BioCryst Pharmaceuticals Inc
      2022   Phase 2   EUCTR2020-004438-39-NL   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-SK   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-HU   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-FR   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-ES   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States
   Biocad
      2019   Phase 3   NCT04060264   Russian Federation
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2019-004931-21-IT   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
   F. Hoffman-La Roche Ltd.
      2022   Phase 3   EUCTR2019-004931-21-RO   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-FR   Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004931-21-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-PL   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-HU   Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004931-21-DE   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      -   Phase 3   EUCTR2019-004931-21-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-000597-26-IE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-FR   Australia;Belgium;Brazil;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-EE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-CZ   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000597-26-BE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-PL   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-GR   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000597-26-DE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
      -   Phase 3   EUCTR2020-000597-26-SE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
   NOVARTIS PHARMA AG
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
   Novartis Pharma AG
      2021   Phase 3   EUCTR2019-004665-40-CZ   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-HU   Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-FR   Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
   NovelMed Therapeutics
      2026   Phase 2   NCT05646563   -
   Regeneron Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-004486-40-RO   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-PL   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-GR   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-PL   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-GR   Brazil;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-FR   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-ES   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-DE   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
   Samsung Bioepis Co., Ltd.
      2019   Phase 3   NCT04058158   India;Korea, Republic of;Malaysia;Mexico;Romania;Taiwan;Thailand;Ukraine
Soliris 300
   Roche Farma S. A. U. que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche Ltd
      2019   Phase 4   EUCTR2019-001453-10-ES   Argentina;Brazil;Canada;Colombia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
Soliris 300 MG concentrate FOR solution FOR infusion
   F. Hoffman-La Roche Ltd.
      2021   Phase 3   EUCTR2019-004931-21-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-000597-26-PT   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
Soliris 300MG/30ML
   Novartis Pharma AG
      2021   Phase 3   EUCTR2019-004665-40-DE   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-NL   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
Stem cell transplantation
   St. Jude Children's Research Hospital
      2003   Phase 2   NCT00145613   United States
Synthetic 15-amino-acid macrocyclic peptide
   Ra Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2016-003522-16-FI   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom
Synthetic 15-amino-acid macrocyclic peptide acylated with A ethyleneglycol24
   Ra Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2016-003523-34-HU   Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003523-34-GB   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003523-34-DK   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003522-16-HU   Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom
      2017   Phase 2   EUCTR2016-003522-16-GB   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom
      2017   Phase 2   EUCTR2016-003522-16-DK   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom
Synthetic 15-amino-acid macrocyclic peptide acylated with A ethyleneglycol24 palmitoylated linker
   Ra Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2016-003523-34-FI   Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States
Synthetic 15-amino-acid macrocyclic peptide acylated with A polyethyleneglycol palmitoylated linker
   Ra Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-003956-19-FI   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Finland;Georgia;Germany;Hong Kong;Italy;Korea, Republic of;Malaysia;Mexico;New Zealand;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;United States
Systematic chemotherapy and antibodies
   St. Jude Children's Research Hospital
      2005   Phase 2   NCT00143559   United States
Systemic chemotherapy and antibodies
   St. Jude Children's Research Hospital
      2003   Phase 2   NCT00145613   United States
Tacrolimus
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States
Tetract-HIB - 1 siringa precaricata 0.5 ML
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-000665-79-IT   Italy;Korea, Republic of;New Zealand;United Kingdom
      2018   Phase 2   EUCTR2016-003526-16-IT   Italy;Korea, Republic of;New Zealand;United Kingdom;United States
Total body irradiation
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
Total-body irradiation
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00397813   Denmark;Germany;Italy;United States
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
      2012   Phase 2   NCT01529827   United States
      2009   -   NCT00856388   United States
Treosulfan
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Tretinoin
   Department of Hematology, Second Medical Center, Chinese PLA General Hospital
      2021   Phase 2   ChiCTR2000039675   Chinese
Ultomiris
   Alexion Pharmaceuticals Inc.
      2020   Phase 4   EUCTR2019-003440-74-GB   United Kingdom
   Alexion Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2017-002820-26-NL   France;Netherlands;Norway;Russian Federation;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002820-26-GB   France;Netherlands;Norway;Russian Federation;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002026-36-NL   Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002025-11-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States Minor Outlying Islands
   Alexion Pharmaceuticals, Inc.
      2024   -   NCT06312644   United States
   Aurand Lisa
      2023   Phase 3   JPRN-jRCT2031220440   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;South Korea;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   BioCryst Pharmaceuticals Inc
      2022   Phase 2   EUCTR2020-004438-39-NL   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-SK   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-HU   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-FR   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004438-39-ES   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States
   Novartis Pharma AG
      2021   Phase 3   EUCTR2019-004665-40-CZ   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-HU   Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
   REGENERON PHARMACEUTICALS, INC.
      2022   Phase 3   EUCTR2020-004486-40-IT   Brazil;Canada;China;Colombia;France;Greece;Hungary;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Singapore;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
   Regeneron Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-004486-40-RO   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-PL   Canada;China;Colombia;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-HU   Brazil;Canada;China;Colombia;France;Greece;Hungary;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-GR   Canada;China;Colombia;France;Greece;Hungary;India;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Peru;Philippines;Poland;Romania;Singapore;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004486-40-ES   Brazil;Canada;China;Colombia;France;Greece;Italy;Japan;Jordan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Singapore;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-PL   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-GR   Brazil;Colombia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-FR   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-ES   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002761-33-DE   Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Taiwan;Turkey;United Kingdom;United States
   Roche Farma S. A. U. que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche Ltd
      2019   Phase 4   EUCTR2019-001453-10-ES   Argentina;Brazil;Canada;Colombia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
Ultomiris - 300 MG - concentrato PER soluzione PER infusione - USO endovenoso - flaconcino (vetro) 3 ML (100 MG / ML) - 1 flaconcino
   BIOCRYST PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-004438-39-IT   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States
Ultomiris 300MG/30ML
   Novartis Pharma AG
      2021   Phase 3   EUCTR2019-004665-40-DE   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-NL   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
Vaccino contro IL memingococco DI gruppo B
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-003172-41-IT   China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States
Vaccino haemophilus influenzae B coniugato CON proteina difterica CRM197
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2016-003526-16-IT   Italy;Korea, Republic of;New Zealand;United Kingdom;United States
Vaccino haemophilus influenzae B coniugato CON tossoidetetanico
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-003172-41-IT   China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States
Vaccino meningococcico polisaccaridico
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-000665-79-IT   Italy;Korea, Republic of;New Zealand;United Kingdom
      2018   Phase 2   EUCTR2016-003526-16-IT   Italy;Korea, Republic of;New Zealand;United Kingdom;United States
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-000888-33-IT   France;Germany;Italy
Vaccino pneumococcico
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004385-19-IT   Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States
      2021   Phase 3   EUCTR2020-003172-41-IT   China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-000888-33-IT   France;Germany;Italy
Vari
   ALEXION PHARMACEUTICALS INC
      2004   -   EUCTR2004-000646-20-IT   Ireland;Italy;Sweden
X-RAY imaging
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
XH-S003 capsule
   S-INFINITY Pharmaceuticals Co., Ltd
      2025   Phase 2   NCT06978699   China
Zilucoplan
   Ra Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-003956-19-FI   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Finland;Georgia;Germany;Hong Kong;Italy;Korea, Republic of;Malaysia;Mexico;New Zealand;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 2   NCT03225287   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003523-34-FI   Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States